<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="50259">
  <!-- This xml conforms to an XML Schema at:
    http://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    http://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on June 04, 2014</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>http://clinicaltrials.gov/show/NCT01867229</url>
  </required_header>
  <id_info>
    <org_study_id>UCL-gyneco-001</org_study_id>
    <nct_id>NCT01867229</nct_id>
  </id_info>
  <brief_title>Breast Cancer and Chemo-amennorhea</brief_title>
  <acronym>chemo-ameno</acronym>
  <official_title>Etude Prospective Multicentrique de l'aménorrhée Chimio-induite et de sa réversibilité Dans le Cancer du Sein Chez Des Patientes préménopausées Recevant Une chimiothérapie Adjuvante ou néoadjuvante. Etude Améno-Chimio.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Cliniques universitaires Saint-Luc- Université Catholique de Louvain</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Cliniques universitaires Saint-Luc- Université Catholique de Louvain</source>
  <oversight_info>
    <authority>Belgium: Institutional Review Board</authority>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Relation between chemotherapy and amennorhea
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date>October 2011</start_date>
  <completion_date type="Anticipated">December 2014</completion_date>
  <primary_completion_date type="Anticipated">December 2013</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Observational</study_type>
  <study_design>Time Perspective: Prospective</study_design>
  <primary_outcome>
    <measure>incidence and duration of the amenorrhea induced by chemotherapy</measure>
    <time_frame>5 years</time_frame>
    <safety_issue>No</safety_issue>
  </primary_outcome>
  <number_of_groups>1</number_of_groups>
  <enrollment type="Anticipated">500</enrollment>
  <condition>Breast Cancer</condition>
  <arm_group>
    <arm_group_label>FEC- TC</arm_group_label>
    <description>Fluorouracil- Epiadriamycine- Cyclophosphamide Taxotère-Cyclophosphamide</description>
  </arm_group>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>observational</intervention_name>
    <description>standard of care fore patients with non metastatic breast cancer</description>
    <arm_group_label>FEC- TC</arm_group_label>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        pre-menauposal breast cancer treated with chemotherapy
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

        pre-menauposal breast cancer needed to be treat with chemotherapy -

        Exclusion Criteria:

        metastases menopausal

        -
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>N/A</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>jean-Pascal Machiels</last_name>
    <role>Principal Investigator</role>
    <affiliation>UCL-Saint Luc</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>jean-pascal Machiels, PhD</last_name>
    <phone>+32 2 764 54 57</phone>
    <email>jean-pascal.machiels@uclouvain.be</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Nathalie Blondeel</last_name>
    <phone>+32 2 764 42 14</phone>
    <email>nathalie.blondeel@uclouvain.be</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Clinique Saint Vincent</name>
      <address>
        <city>Rocourt</city>
        <state>Liège</state>
        <zip>4000</zip>
        <country>Belgium</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Michel Masson</last_name>
    </contact>
    <investigator>
      <last_name>Michel Masson</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Cliniques Universitaires Saint-Luc</name>
      <address>
        <city>Brussels</city>
        <zip>1200</zip>
        <country>Belgium</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Martine Berlière</last_name>
      <phone>+32 2 7641075</phone>
      <email>martine.berlière@uclouvain.be</email>
    </contact>
    <contact_backup>
      <last_name>Nathalie Blondeel</last_name>
      <phone>+32 2 764 42 14</phone>
      <email>nathalie.blondeel@uclouvain.be</email>
    </contact_backup>
    <investigator>
      <last_name>Martine Berlière</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Centre Hospitalier Université de Liège</name>
      <address>
        <city>Liège</city>
        <zip>4000</zip>
        <country>Belgium</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Eric Lifrange</last_name>
      <email>elifrange@chu.ulg.ac.be</email>
    </contact>
    <investigator>
      <last_name>Eric Lifrange</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>CHR Citadelle</name>
      <address>
        <city>Liège</city>
        <zip>4000</zip>
        <country>Belgium</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Annelore Barbeaux</last_name>
      <email>annelore.barbeaux@chrcitadelle.be</email>
    </contact>
    <investigator>
      <last_name>Annelore Barbeaux</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Centre hospitalier Peltzer La Tourelle</name>
      <address>
        <city>Verviers</city>
        <zip>4800</zip>
        <country>Belgium</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Anne-Lore Barbeaux, MD</last_name>
      <email>annelore.barbeaux@chrcitadelle.be</email>
    </contact>
    <investigator>
      <last_name>Anne-Lore Barbeaux, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Institut Claudius Renaud</name>
      <address>
        <city>Toulouse</city>
        <zip>31059</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Henri Roche</last_name>
      <email>roche.henri@claudiusregaud.fr</email>
    </contact>
    <investigator>
      <last_name>Henri Roche</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Florence Dalenc</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Belgium</country>
    <country>France</country>
  </location_countries>
  <verification_date>May 2013</verification_date>
  <lastchanged_date>May 31, 2013</lastchanged_date>
  <firstreceived_date>May 29, 2013</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>pre-menauposal</keyword>
  <keyword>neo-adjuvant or adjuvant chemotherapy</keyword>
  <keyword>no metastases</keyword>
  <is_fda_regulated>No</is_fda_regulated>
  <has_expanded_access>No</has_expanded_access>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Breast Neoplasms</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
